Dr. Antoine Yver is Senior Advisor of Clinical Development at Centessa Pharmaceuticals. Previously, Antoine served as Centessa’s Chairman of Development from March 2022 to June 2024 and Chief Medical Officer from may 2021 to February 2022. Antione has more than 30 years of global experience in the pharmaceutical industry and has led the approvals of 11 drugs, including TAGRISSO®, LYNPARZA®, and ENHERTU®. He led the development of TAGRISSO® in 2 years and 7 months from first human dose to US approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Prior to Centesssa, Antoine served as executive vice president and global head, R&D oncology, and chair of the cancer enterprise at Daiichi Sankyo Company, Ltd. Antoine currently serves as an independent director on the board of Sanofi (NASDAQ: SNY) and as an independent board member on the board of Spotlight Therapeutics.
Previously, Antoine was with AstraZeneca, PLC, most recently serving as senior vice president, global medicine head, oncology, and global medicines development China lead.
Earlier, Antoine held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc., Applied Immune Sciences, Inc., and Chugai-RP.
Antoine is a pediatric oncologist and holds an MD degree from Université Paris-Saclay.
What is Antoine Yver's net worth?
The estimated net worth of Antoine Yver is at least $10.77 million as of June 1st, 2023. Yver owns 783,066 shares of Centessa Pharmaceuticals stock worth more than $10,767,158 as of April 28th. This net worth approximation does not reflect any other investments that Yver may own. Learn More about Antoine Yver's net worth.
How do I contact Antoine Yver?
The corporate mailing address for Yver and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at investorrelations@centessa.com. Learn More on Antoine Yver's contact information.
Has Antoine Yver been buying or selling shares of Centessa Pharmaceuticals?
Antoine Yver has not been actively trading shares of Centessa Pharmaceuticals during the last ninety days. Most recently, Antoine Yver sold 6,500 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $4.45, for a transaction totalling $28,925.00. Following the completion of the sale, the executive vice president now directly owns 783,066 shares of the company's stock, valued at $3,484,643.70. Learn More on Antoine Yver's trading history.
Who are Centessa Pharmaceuticals' active insiders?
Centessa Pharmaceuticals' insider roster includes Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?
In the last year, insiders at the sold shares 36 times. They sold a total of 943,081 shares worth more than $15,626,975.14. The most recent insider tranaction occured on April, 25th when insider Gregory M Weinhoff sold 11,742 shares worth more than $159,808.62. Insiders at Centessa Pharmaceuticals own 11.6% of the company.
Learn More about insider trades at Centessa Pharmaceuticals. Information on this page was last updated on 4/25/2025.
